4//SEC Filing
SOFINNOVA VENTURE PARTNERS VI L P 4
Accession 0001209191-10-015417
CIK 0001316175other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 9:45 PM ET
Size
27.2 KB
Accession
0001209191-10-015417
Insider Transaction Report
Form 4
SOFINNOVA VENTURE PARTNERS VI L P
10% Owner
Transactions
- Conversion
Common Stock
2010-03-04+864,855→ 2,077,353 total - Conversion
Common Stock
2010-03-04+828,323→ 1,212,498 total - Conversion
Common Stock
2010-03-04$5.25/sh+350,056$1,837,794→ 2,663,441 total - Conversion
Series B-2 Convertible Preferred Stock
2010-03-04−864,855→ 0 total→ Common Stock (864,855 underlying) - Conversion
Common Stock
2010-03-04+384,175→ 384,175 total - Award
Common Stock
2010-03-04$6.58/sh+744,496$4,898,784→ 3,563,064 total - Award
Common Stock
2010-03-04$7.00/sh+420,166$2,941,162→ 3,983,230 total - Award
Stock Purchase Warrant
2010-03-04+63,251→ 63,251 totalExercise: $7.00Exp: 2014-09-09→ Common Stock (63,251 underlying) - Conversion
Series A-2 Convertible Preferred Stock
2010-03-04−384,175→ 0 total→ Common Stock (384,175 underlying) - Conversion
Common Stock
2010-03-04$5.25/sh+236,032$1,239,168→ 2,313,385 total - Conversion
Common Stock
2010-03-04$6.58/sh+155,127$1,020,736→ 2,818,568 total - Conversion
Series B-1 Convertible Preferred Stock
2010-03-04−828,323→ 0 total→ Common Stock (828,323 underlying) - Award
Stock Purchase Warrant
2010-03-04+42,167→ 42,167 totalExercise: $7.00Exp: 2014-07-17→ Common Stock (42,167 underlying)
Footnotes (8)
- [F1]Each share of Series A-2 Convertible Preferred Stock was automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV VI LLC") is the general partner of SV VI, and James I. Healy, a director of the issuer, Michael F. Powell, Alain L. Azan and Eric P. Buatois, the managing members of SV VI LLC, may be deemed to share voting and dispositive power over the shares held by SV VI. Such persons and entities disclaim beneficial ownership of shares held by SV VI except to the extent of any pecuniary interest therein.
- [F3]Each share of Series B-1 Convertible Preferred Stock was automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F4]Each share of Series B-2 Convertible Preferred Stock was automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F5]The Series A-2, Series B-1 and Series B-2 Convertible Preferred Stock have no expiration date.
- [F6]The warrants were issued on July 17, 2009 and are immediately exercisable, subject to the satisfaction of certain conditions.
- [F7]The warrants were issued on September 9, 2009 and are immediately exercisable, subject to the satisfaction of certain conditions.
- [F8]The Common Stock was acquired upon conversion of a Senior Secured Convertible Promissory Note exempt from the definition of a derivative security and whose conversion ratio did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering.
Documents
Issuer
Anthera Pharmaceuticals Inc
CIK 0001316175
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001211465
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 9:45 PM ET
- Size
- 27.2 KB